Solara Active Pharma Sciences cash flow

Latest FY26

Cash from operations: ₹153cr−28.2% on FY25
Capital spending: ₹52.8cr+32.2% on FY25
Free cash flow: ₹100cr−42.1% on FY25
Cash from financing: −₹53.6cr−₹180 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	99.7	99.3	103	111
	—	94.8	115	105	90.1
	—	−1.4	−0.8	−2.2	−5.8
	—	4.7	2.7	0.6	0.1
	—	0.2	−1.5	−0.5	−0.4
	—	3.7	−3.3	201	−4.4
	—	−1.1	−1.0	−1.3	−4.0
	—	0.0	41.8	13.1	17.3
	—	−111	19.8	178	−52.8
	—	32.0	−10.0	−20.8	22.5
	—	25.9	−59.4	7.3	38.9
	—	15.2	10.9	12.9	−25.2
Cash from operating activities
	36.9	−7.4	0.5	−488	−44.8
	—	162	213	596	188
	—	155	214	108	143
	—	2.1	0.9	−0.9	−13.5
	—	153	213	109	156
Cash from investing activities
	—	52.8	39.9	41.1	111
	—	0.5	0.0	1.0	1.3
	—	0.0	0.4	0.0	0.0
	—	3.0	0.0	0.0	0.0
	—	0.0	0.0	0.0	1.3
	—	0.1	0.0	0.0	0.0
	—	0.0	1.0	0.0	0.0
	—	0.0	0.0	32.4	17.7
	—	1.0	0.8	3.2	7.4
	—	−44.6	1.0	1.0	5.2
	—	−98.8	−36.8	−3.5	−81.1
Cash from financing activities
	—	159	159	0.0	0.0
	—	49.5	75.0	116	108
	—	166	296	118	131
	—	3.6	2.1	0.0	2.4
	—	—	—	0.9	0.0
	—	92.2	113	103	87.5
	—	0.0	−2.9	0.0	0.0
	—	−53.6	−180	−106	−113
	—	0.5	−4.5	−0.3	−37.7
	—	0.5	−4.5	−0.3	−37.7
	—	—	—	8.4	8.7
Reference items
	234	187	206	−95.2	134
	15.2%	13.6%	16.1%	−7.4%	9.3%
	100	100	173	67.8	44.9
	—	−104	−164	−36.1	—
	₹22.49	₹22.49	₹38.84	₹15.23	₹10.10
	29.07×	—	—	—	—
	—	−20.64×	394.11×	−0.19×	−7.03×
	—	2.1	0.9	−0.9	−13.5
	—	92.2	113	103	87.5

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SOLARA₹653.80

Solara Active Pharma Sciences Limited

· Pharma & Health

₹ CrorePeersINDSWFTLAB DCAL SMSPHARMA HIKAL PANACEABIO SAIPARENT INDOCO UNICHEMLABMcap ₹2,910 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	111.2	103.3	99.3	99.7	—
+ Finance Costs	90.1	105.1	114.8	94.8	—
+ Interest Income	-5.8	-2.2	-0.8	-1.4	—
+ Share-based Payments	0.1	0.6	2.7	4.7	—
+ Unrealised FX (Gain) / Loss	-0.4	-0.5	-1.5	0.2	—
+ Other Non-cash Items	-4.4	200.7	-3.3	3.7	—
+ Other — Cash Effects are Investing / Financing	-4.0	-1.3	-1.0	-1.1	—
Changes in Working Capital
+ Inventories	17.3	13.1	41.8	0.0	—
+ Trade Receivables — Current	-52.8	178.2	19.8	-111.3	—
+ Other Current Assets	22.5	-20.8	-10.0	32.0	—
+ Trade Payables — Current	38.9	7.3	-59.4	25.9	—
+ Other Current Liabilities	-25.2	12.9	10.9	15.2	—
Cash from Operating Activities
Profit Before Tax (per I/S)	-44.8	-488.4	0.5	-7.4	36.9
+ Total Adjustments (incl. Working Capital)	187.5	596.4	213.2	162.4	—
Cash from Operations (pre-tax)	142.7	108.0	213.7	155.0	—
+ Income Taxes Paid	-13.5	-0.9	0.9	2.1	—
Cash from Operating Activities	156.3	108.9	212.8	152.9	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	111.3	41.1	39.9	52.8	—
+ Disp of Fixed Assets	1.3	1.0	0.0	0.5	—
+ Disp of Investment Property	0.0	0.0	0.4	0.0	—
+ Acq of Other Long-term Assets	0.0	0.0	0.0	3.0	—
+ Purchase of Investments (Equity / Debt)	1.3	0.0	0.0	0.0	—
+ Sale of Investments (Equity / Debt)	0.0	0.0	0.0	0.1	—
+ Disp of Subsidiaries / Businesses (net)	0.0	0.0	1.0	0.0	—
+ Loans & Advances Repaid	17.7	32.4	0.0	0.0	—
+ Interest Received — Investing	7.4	3.2	0.8	1.0	—
+ Other Inflows / (Outflows) — Investing	5.2	1.0	1.0	-44.6	—
Cash from Investing Activities	-81.1	-3.5	-36.8	-98.8	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	0.0	0.0	159.0	158.5	—
+ Proceeds from Borrowings	107.7	116.4	75.0	49.5	—
+ Repayment of Borrowings	130.6	118.5	296.4	165.7	—
+ Payment of Lease Liabilities	2.4	0.0	2.1	3.6	—
+ Payment of Finance Lease Liabilities	0.0	0.9	—	—	—
+ Interest Paid	87.5	102.6	113.1	92.2	—
+ Other Inflows / (Outflows) — Financing	0.0	0.0	-2.9	0.0	—
Cash from Financing Activities	-112.8	-105.7	-180.5	-53.6	—
Net Changes in Cash (pre-FX)	-37.7	-0.3	-4.5	0.5	—
Net Changes in Cash	-37.7	-0.3	-4.5	0.5	—
Closing Cash	8.7	8.4	—	—	—
Reference Items
EBITDA	133.9	-95.2	206.3	186.8	233.8
EBITDA Margin %	9.27	-7.38	16.07	13.64	15.23
Free Cash Flow (CFO − Capex)	44.9	67.8	172.9	100.1	100.1
Free Cash Flow to Equity	—	-36.1	-164.1	-103.7	—
Free Cash Flow per Basic Share	10.10	15.23	38.84	22.49	22.49
Price to Free Cash Flow	—	—	—	—	29.07
Cash Flow to Net Income	-7.03	-0.19	394.11	-20.64	—
Cash Paid for Taxes	-13.5	-0.9	0.9	2.1	—
Cash Paid for Interest	87.5	102.6	113.1	92.2	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.